感染

订阅

MedSci主页 / 所有栏目 / 感染

Lancet:登革热疫苗二期临床试验成功

2012-09-12 Derek Wallace 《柳叶刀》

登革热疫苗临床试验诺菲-巴斯德公司
关注

英国医学刊物《柳叶刀》9月11日刊登的报告说，临床试验结果表明，法国疫苗生产商赛诺菲-巴斯德公司研发的登革热疫苗对3种登革热病毒株有预防效果，是一种安全有效的登革热疫苗。 登革热是一种由蚊子传播的急性病毒性传染病，多在热带地区传播，典型症状包括发烧、头痛和关节痛。登革热病毒有4种血清型，人体受到其中任何一种感染后不会对其他3种产生抵抗力。迄今尚无专门预防登革热的疫苗投入使用。 法国赛诺菲－安万

英国医学刊物《柳叶刀》9月11日刊登的报告说，临床试验结果表明，法国疫苗生产商赛诺菲-巴斯德公司研发的登革热疫苗对3种登革热病毒株有预防效果，是一种安全有效的登革热疫苗。

登革热是一种由蚊子传播的急性病毒性传染病，多在热带地区传播，典型症状包括发烧、头痛和关节痛。登革热病毒有4种血清型，人体受到其中任何一种感染后不会对其他3种产生抵抗力。迄今尚无专门预防登革热的疫苗投入使用。

法国赛诺菲－安万特集团旗下从事疫苗研发和生产的赛诺菲－巴斯德公司11日发表公报说，在泰国进行的针对4000多名4岁至11岁儿童的二期临床试验结果表明，该公司研发的疫苗对3种登革热病毒株有预防效果，研究人员正在分析疫苗难以预防第四种病毒株的原因。

公报还说，该公司正在对10个亚洲和拉美国家的3.1万名儿童和青少年进行大规模的三期临床试验，以更好地了解该疫苗在不同流行病学环境下和在更广泛人群中的效力。

据世界卫生组织估计，全球每年有5000万至1亿人感染登革热，其中约50万例是较严重的出血性登革热病例，这种登革热的死亡率较高。

《柳叶刀》杂志认为，赛诺菲－巴斯德研发的“CYD-TDV”活性减毒疫苗有助于实现世卫组织提出的到2020年将登革热死亡率降低50%的目标。

 
链接：
Prof Arunee Sabchareon MD a, Dr Derek Wallace MB BS b , Chukiat Sirivichayakul MD a, Kriengsak Limkittikul MD a, Pornthep Chanthavanich MD a, Saravudh Suvannadabba MD c, Vithaya Jiwariyavej MD d, Wut Dulyachai MD d, Prof Krisana Pengsaa MD a, T Anh Wartel MD e, Annick Moureau MS f, Melanie Saville MB BS f, Alain Bouckenooghe MD b, Simonetta Viviani MD f, Nadia G Tornieporth MD h, Jean Lang MD g.Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. The Lancet,11 September 2012.doi:10.1016/S0140-6736(12)61428

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1827462, encodeId=febf182e46204, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 04 19:02:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662481, encodeId=dde5166248106, content=<a href='/topic/show?id=e3d2e160536' target=_blank style='color:#2F92EE;'>#登革热疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71605, encryptionId=e3d2e160536, topicName=登革热疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23bd25409920, createdName=ms2186806800017884, createdTime=Wed Dec 26 20:02:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940380, encodeId=798a1940380fe, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 11 02:02:00 CST 2013, time=2013-02-11, status=1, ipAttribution=)]
    2013-05-04 howi

    #Lancet#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1827462, encodeId=febf182e46204, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 04 19:02:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662481, encodeId=dde5166248106, content=<a href='/topic/show?id=e3d2e160536' target=_blank style='color:#2F92EE;'>#登革热疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71605, encryptionId=e3d2e160536, topicName=登革热疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23bd25409920, createdName=ms2186806800017884, createdTime=Wed Dec 26 20:02:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940380, encodeId=798a1940380fe, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 11 02:02:00 CST 2013, time=2013-02-11, status=1, ipAttribution=)]
    2012-12-26 ms2186806800017884

    #登革热疫苗#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1827462, encodeId=febf182e46204, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 04 19:02:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662481, encodeId=dde5166248106, content=<a href='/topic/show?id=e3d2e160536' target=_blank style='color:#2F92EE;'>#登革热疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71605, encryptionId=e3d2e160536, topicName=登革热疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23bd25409920, createdName=ms2186806800017884, createdTime=Wed Dec 26 20:02:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940380, encodeId=798a1940380fe, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 11 02:02:00 CST 2013, time=2013-02-11, status=1, ipAttribution=)]
    2013-02-11 jklm09

    #二期临床#

    0